One peptide, tesamorelin, has strong human studies showing it targets harmful fat types like visceral, liver, and muscle fat, not just surface fat.

Scientific Claim

Tesamorelin has robust human evidence demonstrating specific reductions in metabolically harmful fat depots including visceral, liver, and intramuscular fat.

Original Statement

“And I'm guilty of this, too. I talk about early stuff, but there is one peptide where the science has already landed pretty firmly and it doesn't really live on hype. It has real human data. It has longer term studies and it has pretty darn specific effects on like the worst kinds of fat. Not just the fat you can pinch, but the fat that actually disrupts metabolism, your visceral fat, your liver fat, and even fat stored inside the muscle.”

From video:The Most Powerful Peptide for Visceral Belly Fat has Been ReleasedbyThomas DeLauer

Context Details

Domain

pharmacology

Population

human

Subject

tesamorelin

Action

demonstrates

Target

robust human evidence for specific reductions in visceral, liver, and intramuscular fat

Intervention Details

Type: drug

Dosage: 2 mg SC daily

Duration: 6-12 months

Evidence from Studies

Supporting (4)

Unknown Title

Randomized Controlled Trial

Human

This study found that tesamorelin helped reduce dangerous belly fat in HIV patients without harming blood sugar, and the fat didn’t come back while they kept taking it.

Tesamorelin improves fat quality independent of changes in fat quantity

Randomized Controlled Trial

Human

This study shows that tesamorelin helps reduce dangerous belly fat and makes the remaining fat healthier, even if the amount doesn’t change much — which supports the claim that it targets harmful fat.

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Randomized Controlled Trial

Human

This study shows that tesamorelin helps reduce harmful fat in the belly and liver of people with HIV who are taking certain medications.

Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV

Randomized Controlled Trial

Human

2017 Oct 23

Tesamorelin not only reduces belly fat but also improves liver health in people with HIV.

Contradicting (0)

No contradicting evidence found

Similar Assertions

Visceral fat is metabolically active tissue that disrupts insulin sensitivity and metabolic function, and tesamorelin reduces it through mechanisms that improve fat quality, muscle composition, and mitochondrial efficiency, leading to long-term metabolic resilience.

83%

In a 6-month randomized, placebo-controlled trial, tesamorelin significantly reduced both visceral and hepatic (liver) fat, with liver fat reduction being particularly important as it improves insulin sensitivity and glucose metabolism.

83%

Tesamorelin independently increases fat density in visceral and subcutaneous adipose tissue, indicating improved fat quality with smaller adipocytes, better vascularization, reduced hypoxia, and decreased inflammation, independent of fat quantity changes.

81%

A hormone treatment called tesamorelin lowers liver fat by 2.9% more than a placebo in people with HIV who have excess abdominal fat after six months of treatment.

75%

In a 12-month randomized, double-blind, placebo-controlled trial, continued tesamorelin treatment led to an 18% reduction in visceral adipose tissue, while discontinuation resulted in rapid fat regain, demonstrating a direct and reversible cause-and-effect relationship.

75%